Liraglutide ups risk for gallbladder, biliary tract events

(HealthDay)—There is an increased risk for gallbladder- or biliary tract-related events among patients with type 2 diabetes taking liraglutide versus placebo, according to a study published online Aug. 9 in Diabetes Care. Michael A. Nauck, M.D., from St. Josef-Hospital in Bochum, Germany, and colleagues randomly assigned 9,340 patients with type Continue Reading

SGLT-2 inhibitor use not linked to increased risk for UTI events

(HealthDay)—Initiation of therapy with sodium-glucose cotransporter-2 (SGLT-2) inhibitors for type 2 diabetes mellitus is not associated with an increased risk for urinary tract infection (UTI) events compared with initiation of other second-line antidiabetic medications, according to a study published online July 30 in the Annals of Internal Medicine. Chintan V. Continue Reading